

Durvalumab vs Placebo with Stereotactic Body Radiation Therapy in Early Stage NSLC

Status: OPEN TO ACCRUAL

Eligibility Criteria

Age:

Healthy Volunteers:

Conditions & Interventions

Interventions:

drug: Durvalumab, Modality: Immunotherapy

Conditions:

Lung

More Information

Contact(s): Hamilton, Melanie, R - mrhamilton2@vcu.edu

Principal Investigator: Weiss, Elisabeth

Phase: III

IRB

Number: HM20018623

System ID: NCT03833154

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.